Table 4.
Role of prognostic variables and front-line treatments on survival of CML patients by cause of death (CML related or others).
| CML deaths | Other causes | |||||
|---|---|---|---|---|---|---|
| sHR | 95% CI | p | sHR | 95% CI | p | |
| Age (per year) | 1.03 | 0.99-1.07 | 0.176 | 1.03 | 0.99-1.06 | 0.064 |
| Sex (F vs M) | 0.88 | 0.32-2.43 | 0.805 | 0.65 | 0.34-1.27 | 0.207 |
| Charlson C.I. (ref=2) | ||||||
| 3 | 1.49 | 0.47-4.71 | 0.497 | 1.75 | 0.73-4.20 | 0.210 |
| >=4 | 1.18 | 0.34-4.07 | 0.797 | 5.22 | 2.56-10.65 | <0.001 |
| 2GTKI (ref=Imatinib) | 1.61 | 0.52-4.96 | 0.406 | 0.26 | 0.10-0.65 | 0.004 |
| ELTS risk (ref=low) | ||||||
| medium | 2.36 | 0.55-10.05 | 0.245 | 1.50 | 0.71-3.15 | 0.285 |
| high | 9.67 | 2.94-31.74 | <0.001 | 3.11 | 1.52-6.35 | 0.002 |
| Sokal risk (*) | ||||||
| medium | 1.76 | 0.34-9.11 | 0.498 | 0.83 | 0.33-2.08 | 0.688 |
| high | 6.94 | 1.39-34.54 | 0.018 | 1.07 | 0.35-3.24 | 0.909 |
*Estimated in a model including all the covariates in the tables except the ELTS score.
Sub Hazard Ratio (sHR) and 95% Confidence Intervals (CI) estimated with a multivariable Fine and Gray regression model.